Poly(ADP-ribose) Polymerase Inhibitors: all 983 studies that test it
Page 9 of 10. Open to participants first (205), then studies with results posted, then the rest; newest registration first within each.
- A Combination Study of Rucaparib and Atezolizumab in Participants With Advanced Gynecologic Cancers and Triple-Negative Breast CancerCompletedNCT03101280Phase 1
- Biomarker-based Study in R/M SCCHNActive, not recruitingNCT03088059Phase 2
- A Dye for the Detection of Cancer of the Tongue and MouthActive, not recruitingNCT03085147Phase 1/2
- Phase IB Trial of Radium-223 and Niraparib in Patients With Castrate Resistant Prostate Cancer (NiraRad)CompletedNCT03076203Phase 1
- A Study of Fluzoparib Given in Combination With Apatinib in Ovarian or Breast Cancer PatientsCompletedNCT03075462Phase 1
- Food-Effect and Metabolism Study in Healthy SubjectsCompletedNCT03062982Phase 1
- Clinical Trial to Evaluate the Efficacy and Safety of JPI-289 in Patients With Acute Ischemic StrokeStatus unknownNCT03062397Phase 2
- Combination Study of Prexasertib and Olaparib in Patients With Advanced Solid TumorsCompletedNCT03057145Phase 1
- Response to PARP Inhibitor Predicted by the RAD51 AssayWithdrawnNCT03044795Phase 2
- Combination of Carboplatin, Eribulin and Veliparib in Stage IV Cancer PatientsWithdrawnNCT03032614Phase 2
- A Study of Fluzoparib Given in Combination With Apatinib and Paclitaxel in Gastric Cancer PatientsStatus unknownNCT03026881Phase 1
- A Study to Investigate Biomarker Effects of Pre-Surgical Treatment With DNA Damage Repair (DDR) Agents in Patients With Head and Neck Squamous Cell Carcinoma (HNSCC).CompletedNCT03022409Phase 1
- Study of Niraparib and TSR-042 in Recurrent Endometrial CancerActive, not recruitingNCT03016338Phase 2
- Abiraterone/Prednisone, Olaparib, or Abiraterone/Prednisone + Olaparib in Patients With Metastatic Castration-Resistant Prostate Cancer With DNA Repair DefectsActive, not recruitingNCT03012321Phase 2
- Olaparib Monotherapy in Relapsed Small Cell Lung Cancer Patients With HR Pathway Gene Mutations Not Limited to BRCA 1/2 Mutations, ATM Deficiency or MRE11A MutationsCompletedNCT03009682Phase 2
- Safety, Tolerability and Pharmacokinetics of Simmiparib in Patients With Malignant Advanced Solid TumorStatus unknownNCT02993913Phase 1
- Absorption, Metabolism, and Excretion Following a Single Oral Dose of [14C]-RucaparibCompletedNCT02986100Phase 1
- A Study of SC10914 in Patients With Advanced Solid TumorsStatus unknownNCT02940132Phase 1
- A Safety and Pharmacokinetics Study of Niraparib Plus an Androgen Receptor-Targeted Therapy in Men With Metastatic Castration-Resistant Prostate Cancer (BEDIVERE)CompletedNCT02924766Phase 1
- Preoperative Administration of Olaparib With Cisplatin or With Durvalumab or Alone or no Tratment in Patients Who Are Candidates for Surgery of Carcinoma of the Head and Neck.CompletedNCT02882308Phase 2
- Study of Gemcitabine, Carboplatin and VELIPARIB (ABT-888) in Refractory Testicular Germ Cell CancerCompletedNCT02860819Phase 2
- Multi-maintenance Olaparib After Disease Recurrence in Participants With Platinum Sensitive BRCAm High Grade Serous Ovarian CancerCompletedNCT02855697Early Phase 1
- Veliparib, Capecitabine, and Temozolomide in Patients With Advanced, Metastatic, and Recurrent Neuroendocrine TumorWithdrawnNCT02831179Phase 1
- A Feasibility Study of Niraparib for Advanced, BRCA1-like, HER2-negative Breast Cancer PatientsTerminatedNCT02826512Phase 2
- Circulating Tumor DNA Guiding (Olaparib) Lynparza® Treatment in Ovarian CancerStatus unknownNCT02822157Phase 2
- A Phase I Trial of SHR3162 in Subjects With Advanced Solid TumorsCompletedNCT02759666Phase 1
- Safety and Efficacy of Metronomic Cyclophosphamide, Metformin and Olaparib in Endometrial Cancer PatientsCompletedNCT02755844Phase 1/2
- A Phase 1 Trial of SHR3680 With or Without SHR3162 in Prostate CancerCompletedNCT02747342Phase 1
- Pharmacokinetic Drug-Drug Interaction Study of RucaparibCompletedNCT02740712Phase 1
- Pharmacodynamic Study to Assess the Anti-proliferative Activity of the PARP Inhibitor Olaparib in Patients With HPV Positive and HPV Negative HNSCCWithdrawnNCT02686008Phase 1
- Study to Evaluate PM01183 in Combination With Olaparib in Advanced Solid TumorsStatus unknownNCT02684318Phase 1/2
- Olaparib in Locally Advanced ER, PgR and HER2 Negative (Triple Negative) and in Locally Advanced Germline BRCA Mutation-positive Breast Cancer PatientsStatus unknownNCT02681562Phase 2
- A Study of Cediranib and Olaparib at Disease Worsening in Ovarian CancerCompletedNCT02681237Not applicable
- Trial Evaluating Maintenance Olaparib in Patients With Platinum-sensitive Advanced Non-small Cell Lung CancerTerminatedNCT02679963Phase 2
- Planning Treatment for Oesophago-gastric Cancer: a Maintenance Therapy TrialActive, not recruitingNCT02678182Phase 2
- Liposomal Irinotecan and Veliparib in Treating Patients With Solid TumorsCompletedNCT02631733Phase 1
- Talazoparib and HSP90 Inhibitor AT13387 in Treating Patients With Metastatic Advanced Solid Tumor or Recurrent Ovarian, Fallopian Tube, Primary Peritoneal, or Triple Negative Breast CancerWithdrawnNCT02627430Phase 1
- A Phase I Study of Fluzoparib in Patient With Advanced Solid MalignanciesCompletedNCT02575651Phase 1
- PARP-inhibition and CTLA-4 Blockade in BRCA-deficient Ovarian CancerActive, not recruitingNCT02571725Phase 1/2
- Talazoparib in Treating Patients With Advanced or Metastatic Solid Tumors That Cannot Be Removed by Surgery and Liver or Kidney DysfunctionWithdrawnNCT02567396Phase 1
- Open-Label, Randomised, Multi-Drug, Biomarker-Directed, Phase 1b Study in Pts w/ Muscle Invasive Bladder CancerActive, not recruitingNCT02546661Phase 1
- Talazoparib in Combination With Gemcitabine and Cisplatin in Patients With Advanced Solid TumorsWithdrawnNCT02537561Phase 1
- Olaparib as Salvage Treatment for Cisplatin-resistant Germ Cell TumorCompletedNCT02533765Phase 2
- AZD1775 Combined With Olaparib in Patients With Refractory Solid TumorsCompletedNCT02511795Phase 1
- Efficacy and Safety of PARPi to Treat Pancreatic CancerCompletedNCT02511223Phase 2
- A Study to Assess the Efficacy of Rucaparib in Metastatic Breast Cancer Patients With a BRCAness Genomic SignatureCompletedNCT02505048Phase 2
- Study of Tremelimumab Alone or Combined With Olaparib for Patients With Persistent EOC (Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma)TerminatedNCT02485990Phase 1
- Phase I/II Study of the Anti-Programmed Death Ligand-1 Durvalumab Antibody (MEDI4736) in Combination With Olaparib and/or Cediranib for Advanced Solid Tumors and Advanced or Recurrent Ovarian, Triple Negative Breast, Lung, Prostate and Colorectal Can...Active, not recruitingNCT02484404Phase 1/2
- Veliparib in Combination With Carboplatin And Weekly Paclitaxel in Japanese Subjects With Ovarian CancerCompletedNCT02483104Phase 1
- Platine, Avastin and OLAparib in 1st LineCompletedNCT02477644Phase 3
- Absorption, Metabolism, Excretion, and the Determination of Absolute Bioavailability of Niraparib in Subjects With CancerCompletedNCT02476552Phase 1
- Study of Olaparib and Temozolomide in Patients With Recurrent Small Cell Lung Cancer Following Failure of Prior ChemotherapyStatus unknownNCT02446704Phase 1/2
- Phase I of Carboplatin-Olaparib Followed by Olaparib Monotherapy in Advanced CancerCompletedNCT02418624Phase 1
- Trabectedin Plus Olaparib in Metastatic or Advanced Sarcomas (TOMAS)CompletedNCT02398058Phase 1
- Combination of Carboplatin, Eribulin Mesylate, and E7449 in BRCA-Related CancersWithdrawnNCT02396433Phase 1/2
- The Evaluation of Safety, Tolerability and Pharmacokinetics/Pharmacodynamics of JPI-289 in Healthy Male VolunteersCompletedNCT02396069Phase 1
- Olaparib Maintenance Treatment Versus Placebo in Patients With PSR Ovarian Cancer Who Are in CR or PR to Platinum-based Chemotherapy and Whose Tumours Carry sBRCAm or HRR-associated Genes MutationsWithdrawnNCT02392676Phase 3
- Phase 1a/1b BGB-290 for Advanced Solid Tumors.CompletedNCT02361723Phase 1
- Study of BMN-673 With Carboplatin and Paclitaxel in Patients With Advanced BRCA-mutated Solid Tumor or Triple Negative Metastatic Breast CancerTerminatedNCT02358200Phase 1
- A Study of Cediranib and Olaparib at the Time Ovarian Cancer Worsens on OlaparibCompletedNCT02340611Phase 2
- Trial of Olaparib in Combination with AZD5363 (ComPAKT)CompletedNCT02338622Phase 1
- Testing the Addition of the Anti-Cancer Drug Talazoparib to the Combination of Carboplatin and Paclitaxel for the Treatment of Advanced CancerCompletedNCT02317874Phase 1
- Talazoparib in Determining Genetic Effects on Disease Response in Patients With Advanced Ovarian, Fallopian Tube, or Primary Peritoneal CancerCompletedNCT02316834Early Phase 1
- Phase I Study of Olaparib Combined With Cisplatin-based Chemoradiotherapy to Treat Locally Advanced Head and Neck CancerCompletedNCT02308072Phase 1
- SAFIR02_Breast - Efficacy of Genome Analysis as a Therapeutic Decision Tool for Patients With Metastatic Breast CancerActive, not recruitingNCT02299999Phase 2
- Talazoparib in Treating Patients With Recurrent, Refractory, Advanced, or Metastatic Cancers and Alterations in the BRCA GenesActive, not recruitingNCT02286687Phase 2
- Olaparib and Radiotherapy in Head and Neck CancerActive, not recruitingNCT02229656Phase 1
- Olaparib and Radiotherapy in Inoperable Breast CancerCompletedNCT02227082Phase 1
- A Phase 1 Study of Single Agent Veliparib in Japanese Subjects With Advanced Solid TumorsCompletedNCT02210663Phase 1
- A Parp Inhibitor (BMN 673) for Inoperable Advanced eNDometrial cAncerWithdrawnNCT02127151Phase 2
- Dose-Escalation Study of Intraperitoneal (IP) Cisplatin, IV/IP Paclitaxel, IV Bevacizumab, and Oral Olaparib for Newly Diagnosed Ovarian, Primary Peritoneal, and Fallopian Tube CancerCompletedNCT02121990Phase 1
- SAFIR02_Lung - Efficacy of Targeted Drugs Guided by Genomic Profiles in Metastatic NSCLC PatientsCompletedNCT02117167Phase 2
- Study Comparing Veliparib Plus Carboplatin and Paclitaxel Versus Placebo Plus Carboplatin and Paclitaxel in Previously Untreated Advanced or Metastatic Squamous Non-Small Cell Lung CancerCompletedNCT02106546Phase 3
- A Study of Rucaparib in Patients With Pancreatic Cancer and a Known Deleterious BRCA MutationCompletedNCT02042378Phase 2
- A Study Evaluating Safety and Efficacy of the Addition of ABT-888 Plus Carboplatin Versus the Addition of Carboplatin to Standard Chemotherapy Versus Standard Chemotherapy in Subjects With Early Stage Triple Negative Breast CancerCompletedNCT02032277Phase 3
- A Study to Evaluate the Effects of Veliparib on Heart Rhythms in Patients With Solid TumorsCompletedNCT02009631Phase 1
- The Evaluation of Safety, Tolerability and Pharmacokinetics of Stroke Targeting Drug in Healthy VolunteersCompletedNCT01983358Phase 1
- To Determine the Effect of Food on the Pharmacokinetics of Olaparib and the Effect of Olaparib on QT Interval Following Oral Dosing of a Tablet Formulation in Patients With Advanced Solid TumoursCompletedNCT01921140Phase 1
- Veliparib in Combination With Gemcitabine and Intensity Modulated Radiation Therapy in Patients With Pancreatic CancerCompletedNCT01908478Phase 1
- A Study to Evaluate the Safety, Pharmacokinetics and Oral Bio Availability of Veliparib in Subjects With Solid TumorsCompletedNCT01853306Phase 1
- D081AC00001 Food Interaction With Olaparib Capsule in Patients With Solid TumoursCompletedNCT01851265Phase 1
- Parp Inhibitor in Advanced Non-Small Cell Lung Cancer (PIN)Status unknownNCT01788332Phase 2
- Study of BMN 673, a PARP Inhibitor, in Healthy Adult Male VolunteersCompletedNCT01776437Phase 1
- Veliparib and Floxuridine in Treating Patients With Metastatic Epithelial Ovarian, Primary Peritoneal Cavity, or Fallopian Tube CancerCompletedNCT01749397Phase 1
- Veliparib and Topotecan for Relapsed Ovarian Cancer With Negative or Unknown BRCA StatusCompletedNCT01690598Phase 1/2
- TOPARP: A Phase II Trial of Olaparib in Patients With Advanced Castration Resistant Prostate CancerStatus unknownNCT01682772Phase 2
- Olaparib for Patients With Recurrent BRCA Deficient Ovarian CancerWithdrawnNCT01661868Phase 2
- Phase Ib Study of Olaparib Plus Weekly Carboplatin and Paclitaxel in Relapsed Ovarian CancerStatus unknownNCT01650376Phase 1/2
- Phase I Study of the Oral PI3kinase Inhibitor BKM120 or BYL719 and the Oral PARP Inhibitor Olaparib in Patients With Recurrent Triple Negative Breast Cancer or High Grade Serous Ovarian CancerCompletedNCT01623349Phase 1
- Pre-Operative Radiation and Veliparib for Breast CancerCompletedNCT01618357Phase 1
- An Open-Label, Multicenter, Phase 1/2 Study of Poly(ADP-Ribose) Polymerase (PARP) Inhibitor E7449 as Single Agent in Subjects With Advanced Solid Tumors or With B-cell Malignancies and in Combination With Temozolomide (TMZ) or With Carboplatin and Paclitaxel in Subjects With Advanced Solid TumorsCompletedNCT01618136Phase 1/2
- A Study of Veliparib in Combination With Carboplatin and Paclitaxel in Japanese Subjects With Solid TumorsCompletedNCT01617928Phase 1
- Phase 2 Study of the Poly(ADP-Ribose) Polymerase Inhibitor E7016 in Combination With Temozolomide in Subjects With Wild Type BRAF Stage IV or Unresectable Stage III MelanomaTerminatedNCT01605162Phase 2
- Treatment Extension Study for Patients Who Have Previously Participated and Have Benefited From Iniparib in a Clinical TrialCompletedNCT01593228Phase 3
- A Clinical Study Conducted in Multiple Centers Evaluating Escalating Doses of Veliparib in Combination With Capecitabine and Radiation in Patients With Locally Advanced Rectal CancerCompletedNCT01589419Phase 1
- Olaparib Dose Escalating Trial + Concurrent RT With or Without Cisplatin in Locally Advanced NSCLCCompletedNCT01562210Phase 1
- A Clinical Study Conducted in Multiple Centers Comparing Veliparib in Combination With Carboplatin and Paclitaxel Versus a Placebo in Combination With Carboplatin and Paclitaxel in Patients With Advanced Non-small Cell Lung CancerCompletedNCT01560104Phase 2
- Study of ABT-888 in Combination With Bortezomib and Dexamethasone in Patients With Relapsed Refractory MyelomaCompletedNCT01495351Phase 1
- Phase I Study of Olaparib With Cisplatin Based Chemoradiotherapy in Squamous Cell Carcinoma of the Head and NeckWithdrawnNCT01491139Phase 1
- Veliparib With Radiation Therapy in Patients With Inflammatory or Loco-regionally Recurrent Breast CancerCompletedNCT01477489Phase 1